


29<sup>th</sup> International  
**Carbohydrate Symposium**

14<sup>th</sup> – 19<sup>th</sup> July 2018

Faculdade de Ciências, Universidade de Lisboa

**Book of Abstracts**




## THE USE OF FLUOROPROLINE IN MUC1 ANTIGEN ENABLES EFFICIENT DETECTION OF ANTIBODIES IN PATIENTS WITH CANCER

Víctor J. Somovilla,<sup>[a]</sup> Iris A. Bermejo,<sup>[a]</sup> Inês S. Albuquerque,<sup>[b]</sup> Nuria Martínez-Sáez,<sup>[a]</sup> Jorge Castro-López,<sup>[c]</sup> Fayna García-Martín,<sup>[d]</sup> Ismael Compañón,<sup>[a]</sup> Shin-Ichiro Nishimura,<sup>[d]</sup> Jesús Jiménez-Barbero,<sup>[e]</sup> Juan L. Asensio,<sup>[f]</sup> A. Avenzoza,<sup>[a]</sup> J. H. Busto,<sup>[a]</sup> Ramón Hurtado-Guerrero,<sup>[c]</sup> Jesús M. Peregrina,<sup>[a]</sup> Gonçalo J. L. Bernardes<sup>[b,g]</sup> and Francisco Corzana<sup>[a]\*</sup>

- [a] Departamento de Química, Universidad de La Rioja, Centro de Investigación en Síntesis Química, 26006 Logroño, Spain.  
 [b] Instituto de Medicina Molecular, Faculdade de Medicina da, Universidade de Lisboa, 1649-028, Lisboa, Portugal.  
 [c] Institute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, BIFI-IQFR (CSIC), Zaragoza, Spain.  
 [d] Graduate School and Faculty of Advanced Life Science, Field of Drug Discovery Research, Hokkaido University, N21 W11, Sapporo 001-0021, Japan.  
 [e] CIC bioGUNE, Bizkaia Technology Park, Building 801A, 48170 Derio, Spain; (ii) Ikerbasque, Basque Foundation for Science, Maria Diaz de Haro 13, 48009 Bilbao, Spain.  
 [f] Instituto de Química Orgánica General, IQOG-CSIC, 28006 Madrid, Spain.  
 [g] Department of Chemistry, University of Cambridge, CB2 1EW, Cambridge, U.K.

MUC1 is a glycoprotein overexpressed in most types of cancer [1]. This overexpression is associated with elevated concentrations of antibodies against MUC1 in the blood of patients [2].

In this talk, a structure-based design of a new generation tumor-associated glycopeptides with improved affinity against two anti-MUC1 antibodies is described [3]. These unique antigens feature a fluorinated proline residue, such as a (4*S*)-4-fluoro-L-proline or 4,4-difluoroproline, at the most immunogenic domain (see Figure). Binding assays using bio-layer interferometry reveal 3-fold to 10-fold affinity improvement with respect to the natural glycopeptides. According to X-ray crystallography and MD simulations, the fluorinated residues stabilize the antigen-antibody complex by enhancing key CH/ $\pi$  interactions. Interestingly, a notable improvement in detection of cancer-associated anti-MUC1 antibodies from serum of patients with prostate cancer is achieved with the non-natural antigens, which proves that these derivatives can be considered better diagnostic tools than the natural antigen for this type of cancer.



### References

- [1] N. Martínez-Sáez, J. M. Peregrina, F. Corzana, *Chem. Soc. Rev.* **2017**, *46*, 7154-7175.  
 [2] Z.-M. Tang, Z.-G. Ling, C.-M. Wang, Y.-B. Wu, J.-L. Kong, *PLoS One* **2017**, *12*, e0182117.  
 [3] V. J. Somovilla, I. A. Bermejo, I. S. Albuquerque, N. Martínez-Sáez, J. Castro-López, F. García-Martín, I. Compañón, H. Hinou, S.-I. Nishimura, J. Jiménez-Barbero, J. L. Asensio, A. Avenzoza, J. H. Busto, R. Hurtado-Guerrero, J. M. Peregrina, G. J. L. Bernardes, F. Corzana, *J. Am. Chem. Soc.* **2017**, *139*, 18255–18261.